San Francisco Business Times -- Genentech Chairman and CEO Art Levinson, product development chief Susan Desmond-Hellmann and other key executives will leave day-to-day operations of the South San Francisco-based biotech powerhouse following its $47 billion merger last month with Swiss drug maker Roche.
